This comprehensive review explores advancements in the treatment of Triple-Negative Breast Cancer, emphasizing the transformative impact of targeted therapies and immunotherapies and envisions a future where targeted and immune-based interventions redefine TNBC treatment, offering new hope for patients and clinicians alike.
Abstract
This comprehensive review explores advancements in the treatment of Triple-Negative Breast Cancer (TNBC), emphasizing the transformative impact of targeted therapies and immunotherapies. Given TNBC’s aggressive nature and limited therapeutic options, this review provides an in-depth analysis of emerging strategies that aim to enhance patient outcomes. Within targeted therapies, we discuss molecular subtypes and evaluate the efficacy of PARP inhibitors, EGFR inhibitors, and PI3K inhibitors, integrating insights from clinical trials. The immunotherapy landscape is examined through immune checkpoint inhibitors, Chimeric Antigen Receptor (CAR) T-cell therapy, and novel vaccine-based approaches. Combination strategies are assessed, focusing on clinical efficacy, safety, and resistance mechanisms. Additionally, we highlight emerging therapeutic innovations, including bispecific antibodies, advanced drug delivery systems, and personalized medicine approaches. Beyond treatment modalities, the review addresses key challenges such as therapy resistance, biomarker-driven treatment selection, and the integration of Artificial Intelligence in TNBC management. Future directions emphasize ongoing clinical trials and evolving therapeutic paradigms aimed at improving survival and quality of life for TNBC patients. As the field progresses, a multidisciplinary approach integrating precision oncology, innovative therapeutics, and patient-centered care will be critical. In conclusion, this review encapsulates current breakthroughs and envisions a future where targeted and immune-based interventions redefine TNBC treatment, offering new hope for patients and clinicians alike.
Current and emerging treatment approaches based on modulation of the immune response, with particular emphasis on immune checkpoint inhibitors, targeted therapies, and mRNA vaccines are discussed.
Artur Marcysiak, Patrycja Mularczyk, Nina Polek et al.· International Journal of Inn...· 0 citations
This review aims to discuss current and emerging treatment approaches based on modulation of the immune response, with particular emphasis on immune checkpoint inhibitors, targeted therapies, and mRNA vaccines.
Artur Marcysiak, Patrycja Mularczyk, Nina Polek et al.· 1 citation
This framework integrates evidence level, disease stage, biomarker reliability and patient tolerance into treatment selection for TNBC precision therapy and distinguish them from maturing or exploratory strategies such as pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death...
Zi-Xun Wang, Xi-Yu Liu, Yu-Xiao Wu et al.· Journal of Hematology & Onco...· 0 citations
This review examines the evolving landscape of ICI‐based combination therapies, including regimens that combine ICI with chemotherapy, targeted therapy, antibody–drug conjugates, antiangiogenic agents, and radiotherapy, which have expanded first‐line treatment options across multiple solid tumors and, in selected setti...
The current evidence supporting targeted therapies available in Japan, the roles of companion diagnostics and comprehensive genomic profiling (CGP), and treatment strategies based on actionable driver alterations are summarized.
This review encapsulates significant developments in molecularly targeted agents and immune checkpoint inhibitors, emphasising their clinical efficacy, resistance mechanisms, and innovative therapeutic combinations, and reviews pivotal clinical trials and newly filed patents.
K. C. Geervani, R. Maddileti, Kalpi Sania Kausar et al.· Current Drug Discovery Techn...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.